The Pharmaceutical KnowledgeBase (PharmaKB.com) provides research and financial intelligence about companies and their approved drugs as well as drug candidates in clinical trials. In this quarterly PharmaKB report, we provide an update about novel drugs approved by the US FDA in of this year. By referencing new drugs as “novel” the FDA is confirming that the medicine being approved contains ingredients and/or a mechanism of action that the FDA hasn’t previously approved.
2024 | January | February | March
January 2024 – Novel FDA Drug Approvals
Berdazimer
February 2024 – Novel FDA Drug Approvals
Cefepime/enmetazobactam
LetibotulinumtoxinA-wlbg
March 2024 – Novel FDA Drug Approvals
Tislelizumab-jsgr
Resmetirom
Aprocitentan
Givinostat
Sotatercept-csrk
Vadadustat
Danicopan
FDA News Release: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218037Orig1s000ltr.pdf